Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in Taiwanese Adults With TSC-Associated Renal Angiomyolipoma
NCT05252585Phase 4Completed
- Sponsor
- Novartis
- Start
- May 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of everolimus in renal angiomyolipoma (AML), sponsored by Novartis. Started May 2023; status: completed.
02
Drugs
everolimus
03
Conditions
renal angiomyolipoma (AML)
Beyond the preview
Go deeper on NCT05252585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05252585.